Holy Name Medical Center, Montclair University, New Jersey, USA
Research Article
Recurrence of acute migraine following ubrogepant and diclofenac
buffered solution combination therapy- An observational
study
Author(s): James A Charles* and Nicole Suttora
Objective: To analyze the need for a repeat dose following
administration of a single fixed combination dose of ubrogepant and
diclofenac potassium buffered solution for an acute migraine attack.
Background: A relapse after pain freedom/relief from a migraine
abortive is an acute treatment failure. Reduction of acute disability and
prevention of chronification is dependent on effective, rapid, complete
abortive treatment without adverse effects.
Methods: Ubrogepant 100 mg tabs and diclofenac potassium
buffered solution 50 mg powder (UBR/DICb) are both FDA approved
for acute migraine therapy. Twenty-three subjects, 22 female, 1
male with episodic or chronic migraine with and without aura were
instructed take both agents within 15 minutes of the migraine attack.
Pain freedom and pa.. View More»
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 